Researchers have determined that two Phase 1 drugs (CX-4945 and JQ1) can work together to efficiently kill T-cell acute lymphoblastic leukemia cells while having minimal impact on normal blood cells.
Oct 24, 2016
0
0
Since the day they came home from the hospital in matching newborn monkey outfits, Zane and Zac Taylor have done everything together.
Sep 23, 2016
0
3
(HealthDay)—A new T-cell immunotherapy has led to sustained regression in many previously relapsing and treatment-resistant cases of acute lymphoblastic leukemia, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia, ...
Feb 17, 2016
0
5
The move to make cancer treatments gentler for children has paid a double dividend: More kids are surviving than ever before, and without the long-term complications that doomed many of their peers a generation ago, new research ...
Jun 1, 2015
0
78
(HealthDay)—Articles relating to malignant hematology, transfusion medicine, and bleeding and clotting disorders are included in a special update summary published online April 30 in the Annals of Internal Medicine.
May 8, 2015
0
19
Two new cancer studies out of Dalhousie Medical School have shown success in testing safer, less toxic treatments for a rare form of pediatric leukemia called T-cell acute lymphocytic leukemia (T-ALL). The studies were published ...
Apr 17, 2015
0
34
Almost all patients with a group of blood cancers called B-cell malignancies have two prominent "fingerprints" on the surface of leukemia and lymphoma cancers, called CD22 and CD19, Vallera explained. To develop the drug, ...
Mar 13, 2015
0
8
A promising method of immunotherapy to treat children with relapsed acute lymphocytic leukemia (ALL) is opening at the University of Wisconsin Carbone Cancer Center and American Family Children's Hospital. The trial is open ...
Feb 25, 2015
0
14
US regulators on Monday put an experimental immunotherapy agent on the fast track to market approval, after 89 percent of leukemia patients in early trials saw their cancers disappear.
Jul 7, 2014
1
0
An estimated 25 percent of children in remission from acute lymphocytic leukemia (ALL) are missing too many doses of an essential maintenance medication that minimizes their risk of relapse, according to a study published ...
Jun 2, 2014
0
0
